CA2144651A1 - Cellules immortalisees et leurs applications - Google Patents

Cellules immortalisees et leurs applications

Info

Publication number
CA2144651A1
CA2144651A1 CA002144651A CA2144651A CA2144651A1 CA 2144651 A1 CA2144651 A1 CA 2144651A1 CA 002144651 A CA002144651 A CA 002144651A CA 2144651 A CA2144651 A CA 2144651A CA 2144651 A1 CA2144651 A1 CA 2144651A1
Authority
CA
Canada
Prior art keywords
immortalized
cell
tick
antigen
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002144651A
Other languages
English (en)
Inventor
Timothy J. Miller
Stephen K. Wikel
Rangappa N. Ramachandra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma State University
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2144651A1 publication Critical patent/CA2144651A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Insects & Arthropods (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002144651A 1992-09-14 1993-09-14 Cellules immortalisees et leurs applications Abandoned CA2144651A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94487392A 1992-09-14 1992-09-14
US07/944,873 1992-09-14

Publications (1)

Publication Number Publication Date
CA2144651A1 true CA2144651A1 (fr) 1994-03-31

Family

ID=25482205

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002144651A Abandoned CA2144651A1 (fr) 1992-09-14 1993-09-14 Cellules immortalisees et leurs applications

Country Status (5)

Country Link
EP (1) EP0749319A1 (fr)
JP (1) JPH08502646A (fr)
AU (2) AU5103293A (fr)
CA (1) CA2144651A1 (fr)
WO (1) WO1994006463A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
US6017757A (en) * 1997-02-20 2000-01-25 Mississippi State University Isolated viable nematode intestinal cells
IL142164A0 (en) 1998-09-23 2002-03-10 Zymogenetics Inc Cytokine receptor zalpha11
AU764039B2 (en) 1998-12-07 2003-08-07 Zymogenetics Inc. Growth factor homolog ZVEGF3
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DE60043626D1 (de) 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
EP1881070B1 (fr) 1999-03-09 2012-10-03 Zymogenetics, Inc. Cytokine humaine en tant que ligand du récepteur zalpha et ses utilisations
DE60043944D1 (de) 1999-12-23 2010-04-15 Zymogenetics Inc Zytokin zcyt018
CA2412239C (fr) 2000-06-26 2013-05-28 Zymogenetics, Inc. Zcytor17, recepteur de la cytokine
DK1451322T3 (da) 2001-11-05 2010-02-01 Zymogenetics Inc Il-21-antagonister
AU2003280410B8 (en) 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
EP2295455A1 (fr) 2002-04-19 2011-03-16 ZymoGenetics, L.L.C. Récepteur de cytokine
EP1927600A1 (fr) 2003-08-07 2008-06-04 Zymogenetics, Inc. Propositions homogènes de IL-28 et IL-29
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
CA2574564C (fr) 2004-07-29 2013-04-16 Zymogenetics, Inc. Utilisation des molecules il-28 et il-29 pour traiter le cancer et les troubles autoimmuns
EP1922079A2 (fr) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
AU2006278229B2 (en) 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
JP2009537563A (ja) 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
CN101511859A (zh) 2006-06-02 2009-08-19 惠氏公司 TGF-β超家族的蛋白质和肽用于纯化和治疗方法的用途
US7754689B2 (en) 2006-06-02 2010-07-13 Wyeth Llc Finger-1 peptide analogs of the TGF-β superfamily
BRPI0719360B1 (pt) * 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
US20100240597A1 (en) 2007-06-15 2010-09-23 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
WO2009120922A2 (fr) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions et procédés pour inhiber pdgfr-bêta et vegf-a
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド 可溶性ハイブリッドＦｃγレセプターおよび関連する方法
US8822642B2 (en) 2010-06-09 2014-09-02 Zymogenetics, Inc. Dimeric fusion proteins and related compositions and methods
SG10201606285YA (en) 2012-02-01 2016-09-29 Synthetic Genomics Inc Materials and methods for the synthesis of error-minimized nucleic acid molecules
WO2017044424A1 (fr) 2015-09-08 2017-03-16 Theripion, Inc. Polypeptides de fusion apoa-1 ainsi que compositions et procédés associés
EP3352760B1 (fr) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Polypeptides de liaison à cd3
WO2018136163A2 (fr) 2016-12-09 2018-07-26 Theripion, Inc. Polypeptides de fusion apoa-1 en tandem
SG11202000503QA (en) 2017-07-20 2020-02-27 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
BR112020012364A2 (pt) 2017-12-20 2020-11-24 Harbour Biomed (Shanghai) Co., Ltd anticorpos de ligação a ctla-4 e usos dos mesmos
EP3732190B1 (fr) 2017-12-27 2025-08-06 Imunami Laboratories Pte. Ltd. Polypeptides recombinants et leurs procédés d'utilisation
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
WO2021040610A1 (fr) 2019-08-26 2021-03-04 Imunami Laboratories Pte. Ltd. Polypeptides recombinants et leurs méthodes d'utilisation
EP4168034B1 (fr) 2020-06-22 2025-11-26 Imunami Laboratories Pte. Ltd. Alpha-a-crystallin recombinante et combinaisons pour utilisation dans le traitement du cancer
US12180521B2 (en) 2021-02-19 2024-12-31 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途
WO2024259220A1 (fr) 2023-06-15 2024-12-19 Theripion, Inc. Polypeptides de fusion de pon3 et de pon1 évoluée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447537A (en) * 1981-01-22 1984-05-08 The United States Of Americas As Represented By The Department Of Health And Human Services Tick cell lines
IL84574A (en) * 1986-11-27 1994-10-07 Biotech Australia Pty Ltd Beef tick antigen, its parts, homologous vapitopios with similar immune activity, process for their preparation, polynucleotide encoding them, vaccines containing them, antibodies derived from
US5186933A (en) * 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system

Also Published As

Publication number Publication date
EP0749319A4 (fr) 1996-09-16
AU4831497A (en) 1998-03-26
EP0749319A1 (fr) 1996-12-27
JPH08502646A (ja) 1996-03-26
WO1994006463A1 (fr) 1994-03-31
AU5103293A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
CA2144651A1 (fr) Cellules immortalisees et leurs applications
Williams et al. Immunological and biological characterization of Coxiella burnetii, phases I and II, separated from host components
Pinto et al. Immune response to virus-infection-associated (VIA) antigen in cattle repeatedly vaccinated with foot-and-mouth disease virus inactivated by formalin or acetylethyleneimine
Gottstein et al. Antigenic variation in Giardia lamblia: cellular and humoral immune response in a mouse model
US4596707A (en) Babesia parasite antigen useful in vaccine and diagnostic reagent
Mellor et al. Experimental transmission of African swine fever virus by Ornithodoros savignyi (Audouin)
US8034571B1 (en) Microbial polynucleotides expressed during infection of a host
Lewis, BD*, Penzhorn, BL** & Lï¿ ½pez Rebollar Immune responses to South African Babesia canis and the development of a preliminary vaccine
Finlay et al. The use of the complement fixation test for rapid typing of infectious pancreatic necrosis virus
CN118480515B (zh) 一种猪繁殖与呼吸综合征病毒nadc30病毒株及其应用
US7033748B2 (en) Identification of microbial polynucleotides expressed during infection of a host
Uchida et al. Immunofluorescence test with Rickettsia montana for serologic diagnosis of rickettsial infection of the spotted fever group in Shikoku, Japan
US4759927A (en) Vaccine against Potomac horse fever and method of preparation therefore
KR20100070334A (ko) 아나플라즈마타세아 과의 박테리아 종의 배양 방법
JPH02295934A (ja) イヌコロナウイルスワクチン
US11623945B2 (en) Immunostimulating compositions and uses therefore
Wainberg et al. Immune selection of tumor cell variants in chickens bearing tumors induced by avian sarcoma virus
RU2026343C1 (ru) Вакцина против бруцеллеза сельскохозяйственных животных
RU2798283C1 (ru) Штамм Chlamydia abortus "Chlamydia VNITIBP-21" для производства иммунобиологических лекарственных препаратов
RU2802251C1 (ru) Вакцинная композиция для профилактики энзоотического аборта у овец
CN118931848B (zh) 一种猪圆环病毒3型病毒株及其应用
RU2341288C1 (ru) СРЕДСТВО, ОБЛАДАЮЩЕЕ СВОЙСТВОМ ФОРМИРОВАТЬ КЛЕТОЧНЫЙ ИММУНИТЕТ ПРОТИВ MYCOBACTERIUM TUBERCULOSIS H37 Rv, СПОСОБ ПОЛУЧЕНИЯ ЕГО (ВАРИАНТЫ), РЕКОМБИНАНТНЫЙ ШТАММ И СРЕДСТВО ДЛЯ ДИАГНОСТИКИ ТУБЕРКУЛЕЗА
RU2026081C1 (ru) Вакцина против бруцеллеза сельскохозяйственных животных
RU2230567C2 (ru) Вакцина против аспергиллёза
JPH0118885B2 (fr)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead